The COVID-19 pandemic has been a real boon to Pfizer. Not only has it doubled Pfizer’s annual revenue, it has also given the drugmaker unique weight in determining U.S. health policy — something that concerns even staunch vaccine-pushers like Dr. Paul Offit.
Pfizer’s revenue in 2021 was $81.3 billion — approximately double that of 2020 — and the COVID shot accounted for $36.78 billion of that.
Pfizer’s COVID jab dominates 70% of the U.S. and European markets, and Paxlovid, its COVID drug, has become a standard treatment choice in hospitals. This despite findings showing the shot doesn’t prevent infection or transmission, and that Paxlovid causes severe rebound and supercharges mutations.
The U.S. had thrown away 82.2 million expired COVID jab doses as of mid-May 2022, yet the Biden administration ordered another 105 million doses at the end of June 2022 for a fall booster campaign that will cost taxpayers $3.2 billion.
Pfizer’s contracts are almost exclusively slanted in Pfizer’s favor. They’re guaranteed payment while having no financial liability for injuries and deaths, and it appears this indemnification applies even if they were to be found guilty of fraud.